NRIX News and Press, Nurix Therapeutics Inc.

2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-07-11 16:21:37 ET More on Nurix Therapeutics Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies Earnings week ahead: PepsiCo, Delta Air Lines, JPMorgan, C...

Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...

SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...

2024-07-07 08:02:00 ET Roberts Berzins, a Seeking Alpha author, expressed caution regarding Saratoga Investment ( SAR ) by stating, "After the release of Q4 2024 earnings, there is still an insufficient base of positive data points that would justify going long SAR. Currently, SAR i...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...

2024-06-19 09:27:56 ET Summary Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional smal...

2024-06-17 15:24:57 ET More on Nurix Therapeutics Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies Nurix Therapeutics files for mixed shelf securities offering Seeking Alpha’s Quant Rating on Nurix Therapeutics Historical...

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal t...

SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., P...